[go: up one dir, main page]

WO2014141298A3 - Stable pharmaceutical composition of fingolimod - Google Patents

Stable pharmaceutical composition of fingolimod Download PDF

Info

Publication number
WO2014141298A3
WO2014141298A3 PCT/IN2014/000153 IN2014000153W WO2014141298A3 WO 2014141298 A3 WO2014141298 A3 WO 2014141298A3 IN 2014000153 W IN2014000153 W IN 2014000153W WO 2014141298 A3 WO2014141298 A3 WO 2014141298A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
pharmaceutical composition
stable pharmaceutical
present
bioequivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000153
Other languages
French (fr)
Other versions
WO2014141298A2 (en
Inventor
Kapil AGNIHOTRI
Balvir SINGH
Ashish Sehgal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astron Research Ltd
Original Assignee
Astron Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astron Research Ltd filed Critical Astron Research Ltd
Publication of WO2014141298A2 publication Critical patent/WO2014141298A2/en
Publication of WO2014141298A3 publication Critical patent/WO2014141298A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This present invention relates to stable pharmaceutical composition of fingolimod or its pharmaceutically acceptable salts thereof and process for preparation of the same. The pharmaceutical compositions as disclosed in the present invention can be dispensed as an oral dosage form, which are bioequivalent to the marketed Fingolimod product.
PCT/IN2014/000153 2013-03-11 2014-03-10 Stable pharmaceutical composition of fingolimod Ceased WO2014141298A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN725/MUM/2013 2013-03-11
IN725MU2013 2013-03-11

Publications (2)

Publication Number Publication Date
WO2014141298A2 WO2014141298A2 (en) 2014-09-18
WO2014141298A3 true WO2014141298A3 (en) 2014-12-24

Family

ID=51538248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000153 Ceased WO2014141298A2 (en) 2013-03-11 2014-03-10 Stable pharmaceutical composition of fingolimod

Country Status (1)

Country Link
WO (1) WO2014141298A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089341A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Organic compounds
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
US20100040678A1 (en) * 2006-09-26 2010-02-18 Michael Ambuhl Organic compounds
WO2012135561A1 (en) * 2011-04-01 2012-10-04 Novartis Ag Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089341A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Organic compounds
US20100040678A1 (en) * 2006-09-26 2010-02-18 Michael Ambuhl Organic compounds
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2012135561A1 (en) * 2011-04-01 2012-10-04 Novartis Ag Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Also Published As

Publication number Publication date
WO2014141298A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2021011906A (en) Delayed release compositions of linaclotide.
NZ709958A (en) Enhanced stability of novel liquid compositions
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
IL227024A (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives, process for the preparation of such compounds, uses thereof in the preparation of pharmaceuticals and pharmaceutical compositions comprising the same
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IL262494A (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
WO2014166836A8 (en) Growth hormone compound formulation
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX370184B (en) Pharmaceutical composition comprising fingolimod.
WO2014122671A3 (en) Solid oral compositions of saxagliptin
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
WO2012120541A3 (en) Amorphous form of lopinavir and ritonavir mixture
IN2013MU03123A (en)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14764027

Country of ref document: EP

Kind code of ref document: A2